Organization
One Clinical Research, Perth, Australia
1 abstract
Abstract
Efficacy and safety of LM-108, an anti-CCR8 monoclonal antibody, in combination with an anti-PD-1 antibody in patients with gastric cancer: Results from phase 1/2 studies.Org: Peking University Cancer Hospital and Institute, Beijing, China, The First Affiliated Hospital of Henan University of Science and Technology, Shanghai East Hospital, Zhongnan Hospital of Wuhan University, The First Affiliated Hospital of Xinxiang Medical University,